Skip to main
INCY

Incyte (INCY) Stock Forecast & Price Target

Incyte (INCY) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 32%
Buy 16%
Hold 47%
Sell 5%
Strong Sell 0%

Bulls say

Incyte is positioned for continued growth and success, with a strong pipeline and an established track record of commercial success. With leading drugs in multiple indications, including a partnership with Novartis, and a new dermatology product approved for two conditions in 2021 and 2022, Incyte's potential for revenue generation is significant. The company has also seen strong uptake in new patients and high demand for its drugs, and has a clear strategy for continued growth and expansion in the coming years. With a projected revenue of $4.7-$4.9 billion in 2026 and a potential peak sales estimate of $1 billion for its oral option for HS, Incyte represents a solid investment opportunity in the biotech sector.

Bears say

Incyte is a biopharmaceutical company with a successful lead product, Jakafi, and a diverse product pipeline focused on rare blood cancers, graft versus host disease, and dermatology. Despite acknowledging some side effects at a higher dose, Incyte believes that having flexibility in dosing could help with market positioning and attracting physicians. While concerns may arise from Opzelura's lighter-than-expected guidance, Incyte's long-term goal of doubling the size of its business appears achievable through current indication-specific growth and international expansion efforts. Additionally, the company's late-stage oncology portfolio is undervalued, with upcoming data disclosures for several key assets in 2026. However, the near-term catalyst calendar is light, and exclusions of certain products like '734 and Jakafi XR in the financial analysis may impact future revenue and growth.

Incyte (INCY) has been analyzed by 19 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 16% recommend Buy, 47% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Incyte (INCY) Forecast

Analysts have given Incyte (INCY) a Buy based on their latest research and market trends.

According to 19 analysts, Incyte (INCY) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $104.37, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $104.37, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Incyte (INCY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.